Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, Bergh J, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Zhu Y, Pan W, Tryfonidis K, Schmid P.
Pusztai L, et al. Among authors: kummel s.
Ann Oncol. 2024 Feb 17:S0923-7534(24)00046-2. doi: 10.1016/j.annonc.2024.02.002. Online ahead of print.
Ann Oncol. 2024.
PMID: 38369015